Cargando…

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

The course of multiple myeloma (MM) is influenced by a variety of factors, including the specificity of the tumour microenvironment (TME). The aim of this review is to provide insight into the interplay of treatment modalities used in the current clinical practice and TME. Bortezomib-based triplets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bila, Jelena, Katodritou, Eirini, Guenova, Margarita, Basic-Kinda, Sandra, Coriu, Daniel, Dapcevic, Milena, Ibricevic-Balic, Lejla, Ivanaj, Arben, Karanfilski, Oliver, Zver, Samo, Beksac, Meral, Terpos, Evangelos, Dimopoulos, Meletios Athanassios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432054/ https://www.ncbi.nlm.nih.gov/pubmed/34501388 http://dx.doi.org/10.3390/jcm10173940

Ejemplares similares

P981: DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES OF MYELOMA PATIENTS <50 YEARS OF AGE: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP
por: Kastritis, Efstathios, et al.
Publicado: (2023)

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
por: Beksac, Meral, et al.
Publicado: (2020)

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
por: Beksac, Meral, et al.
Publicado: (2021)

P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients
por: Ibricevic-Balic, Lejla, et al.
Publicado: (2016)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Insights on Multiple Myeloma Treatment Strategies
por: Mateos, María-Victoria, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Drug Targeting of Genomic Instability in Multiple Myeloma
por: Beksac, Meral, et al.
Publicado: (2020)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
por: Beksac, Meral, et al.
Publicado: (2023)

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
por: Kozelj, Mirta, et al.
Publicado: (2013)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
por: Melea, Pelagia I., et al.
Publicado: (2014)

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making
por: Gonzalez-McQuire, Sebastian, et al.
Publicado: (2019)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

Metabolic Disorders in Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses
por: Georgakopoulou, Rebecca, et al.
Publicado: (2021)

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

First Experience of (11)C-Methionine PET in Multiple Myeloma in Turkey
por: Özkan, Elgin, et al.
Publicado: (2022)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9o41udcjtl406n2suatbn906ll